Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
- Conditions
- Schizophrenia
- Interventions
- Device: TMS
- Registration Number
- NCT04807530
- Lead Sponsor
- University of California, San Francisco
- Brief Summary
This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how modulation of mPFC activity impacts the larger self-agency network to mediate changes in self-agency judgments. Our overall hypothesis is that increased mPFC excitability by active high-frequency nrTMS in HC and SZ will induce behavioral improvements in self-agency and neural changes in the larger self-agency network that will generalize to improvements in overall cognition, symptoms and daily functioning, and will likely lead to the development of new effective neuromodulation therapies in patients with schizophrenia.
- Detailed Description
This longitudinal mechanistic randomized controlled trial in patients with schizophrenia (SZ) and matched healthy controls (HC) examines the underlying cause of self-agency deficits in SZ and their responsiveness to navigated repetitive transcranial magnetic stimulation (nrTMS) of the medial prefrontal cortex. Using a multimodal neuroimaging approach that combines structural MRI with functional magnetoencephalography imaging (MEGI) and nrTMS that is integrated with cognitive and clinical assessments, this research provides an unprecedented rigorous assessment of the neural and cognitive basis of self-agency and its modulation by nrTMS, using two distinct and validated paradigms involving speech monitoring (pitch perturbation) and reality monitoring.
Subjects will first be assessed for 1 week for diagnostic inclusion criteria and eligibility assessment. They will complete baseline assessments (i.e., cognitive, clinical and daily functioning assessments, structural MRI, and MEGI scans while they perform reality and speech monitoring tasks). After baseline assessments, 80 SZ and 80 age, gender, and education-matched HC will be randomly assigned to either active 10Hz nrTMS targeting mPFC (40HC and 40SZ) or nrTMS targeting a control posterior parietal site (40HC and 40SZ). For the parietal site, the investigators will use the same TMS protocol parameters as the active nrTMS condition. Between and within group analyses will utilize repeated measures mixed-effects models to examine durability and generalizability of behavioral, cognitive, clinical and whole-brain neural oscillatory network changes (with focus on mPFC) after neuromodulation by active nrTMS at proximal, and distal post-nrTMS time-points, compared to control nrTMS of parietal site and baseline. Whole-brain correlations will be computed between neural activity (e.g., with focus on mPFC) related to self-agency during reality and speech monitoring tasks and behavior (e.g., self-generated retrieval accuracy and corrective response magnitude), and between neural activity with cognition, clinical symptoms and daily functioning).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 160
All Subjects:
- Good general physical health
- English is first language
- No neurological disorder
- Meets MRI criteria
- No current alcohol or substance use disorder
Schizophrenia participants:
- Schizophrenia diagnosis of any illness duration,
- Clinical stability, defined as 12 weeks outpatient status and 4 weeks low to moderate dose of antipsychotic medication (<1000 mg. chlorpromazine equivalents), plus stable doses of all other psychotropic medications
All Subjects:
- Implanted metallic parts of implanted electronic devices
- Pregnant or trying to become pregnant
- Any condition that would prevent the subject from giving voluntary informed consent
- Scalp wounds or infections
- Claustrophobia precluding MRI
- Ongoing seizures
- Neurological disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Posterior Parietal TMS TMS 10 Hz high frequency TMS applied to the posterior parietal cortex Medial/Superior Prefrontal TMS TMS 10 Hz High frequency TMS applied to the mPFC
- Primary Outcome Measures
Name Time Method Self-Agency Behavioral Change during Speech Monitoring after TMS vs Baseline (metrics of speech perturbation units) From baseline, to immediately after TMS, up to 1 week Change in speech corrective responses during altered vs. unaltered auditory feedback, measured in units of speech perturbation (cents) from baseline to post-TMS. No scales used.
Self-Agency Behavioral Change during Reality Monitoring after TMS vs Baseline (metrics of accuracy) From baseline, to immediately after TMS, up to 1 week Change in retrieval accuracy of self-generated information during reality monitoring task from baseline to post-TMS. No scales used.
MEGI Neural Activity Change related to Self-Agency during Speech Monitoring after TMS vs Baseline (metrics of neural beta activation units) From baseline, to immediately after TMS, up to 1 week Whole-brain neural activity related to self-agency by contrasting oscillatory activity related to speech onset during altered auditory feedback with activity related to speech onset during unaltered auditory feedback (with focus on mPFC and parietal cortices for ROI analyses) measured in beta weights neural signal change from baseline to post-TMS. No scales used.
MEGI Neural Activity Change related to Self-Agency during Reality Monitoring after TMS vs Baseline (metrics of neural beta activation units) From baseline, to immediately after TMS, up to 1 week Whole-brain neural activity change related to self-agency by contrasting oscillatory activity during encoding and retrieval of self-generated information with encoding and retrieval of externally-derived information (with focus on mPFC and parietal cortices as our region-of-interest (ROI)), measured in beta weights neural signal change from baseline to post-TMS. No scales used.
- Secondary Outcome Measures
Name Time Method Cognition Change after TMS vs Baseline (metrics units of accuracy and speed of processing) From baseline to immediate and distal time points after TMS, up to 4 weeks The PENN Cognitive battery is a validated assessment of cognition in which accuracy scores and reaction times will computed after TMS compared to baseline.The PENN Cognitive battery includes 10 brief cognitive tests, and the score ranges between 0 (worst possible performance) and 1000 (best possible performance).
Daily Functioning Change after TMS vs. Baseline (metrics of functioning) From baseline to immediate and distal time points after TMS, up to 4 weeks Daily functioning will be measured with the Global Assessment of Functioning (GAF) scale over the past week, after TMS compared to baseline. Possible score range from 0 (inadequate information or in persistent danger of severely hurting self or others) to 100 (superior functioning in a wide range of activities)
Clinical Symptom Change after TMS vs Baseline (metrics units of severity) From baseline to immediate and distal time points after TMS, up to 4 weeks Clinical Symptom Change will be measured by the validated SAPS and SANS over the past week after TMS compared to baseline. Possible scores depending on the sub scale can range from 0(Absent) to 7 (Extreme).
Trial Locations
- Locations (1)
UCSF
🇺🇸San Francisco, California, United States